Replies to post #376882 on Anavex Life Sciences Corp (AVXL)

[12x]

So the claim that the PDD ph2 failed the primary endpoint is NOT because clinical efficacy as measured by primary cognitive efficacy endpoints, CDR system Continuity of Attention (CoA) (p = 0.029) as reported by the PR below but the fact Anavex has never reported the COA scores?

ANAVEX®2-73 treatment resulted in significant (p = 0.035) mRNA expression increase of SIGMAR1, the gene encoding for the receptor targeted by ANAVEX®2-73, which correlated with clinical efficacy as measured by primary cognitive efficacy endpoints, CDR system Continuity of Attention (CoA) (p = 0.029) and CDR system Power of Attention (PoA) (p = 0.015), and secondary Parkinson’s efficacy endpoints Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS)[4], MDS-UPDRS Part III (p = 0.024) and MDS-UPDRS Total (p = 0.038).

[georgejjl]

NONSENSE

The COA (Clinical Outcome Assessment) is made up of the MDS-UPDRS Score for Parts I through III with the addition of the patient diary.

Look at the box and whisker plot graphs at the bottom of the second column at the link below:

MDS-UPDRS Score for Parts I through IV show improvement from baseline in patients on high dose compared to placebo

https://www.arianapharma.com/wp-content/uploads/2022/03/79bcf7_ff6b864593fb4418ab306474dd535d35.pdf

The Anavex Phase 2 trial for the treatment of PDD with Blarcamesine met all end points with statistical significance and clinically meaningful outcomes.

GOD bless,